Discover 1,192 paid clinical trials in Murfreesboro, Tennessee. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,192
Active & Responsive
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
for
Small Cell Lung Cancer
Location: Nashville TN, Chicago IL, Buffalo NY, Hackensack NJ,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06780137
Phase1, Phase2, Recruiting
Active & Responsive
Child to Adult Neurodevelopment in Gene Expanded Huntington's Disease
for
Huntington's Disease
Location: Nashville TN, Iowa City IA, Houston TX, Philadelphia PA,
Sponsor: Peggy C Nopoulos
Sex: All
Age: 6 - 30
Code: NCT01860339
Recruiting
Active & Responsive
Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer
for
NSCLC, NSCLC Stage IV, NSCLC Stage IIIB,
Location: Nashville TN, Atlanta GA, St Louis MO, Charleston SC,
Sponsor: Mythic Therapeutics
Sex: All
Age: 18+
Code: NCT05652868
Phase1, Recruiting
Active & Responsive
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
Location: Nashville TN, Lexington KY, Atlanta GA, Germantown TN,
Sponsor: Orchestra BioMed, Inc
Sex: All
Age: 18+
Code: NCT06059638
Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
for
Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer,
Location: Nashville TN, Louisville KY, Atlanta GA, Chicago IL,
Sponsor: Inhibrx Biosciences, Inc
Sex: All
Age: 18+
Code: NCT04198766
Phase1, Phase2, Recruiting
Active & Responsive
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors